M Albertelli, G Rossi, E Nazzari, C Genova, F Biello, E Rijavec, M G Dal Bello, L Patti, M Tagliamento, G Barletta, P Morabito, M Boschetti, A Dotto, D Campana, D Ferone, F Grossi
PURPOSE: Immune checkpoint inhibitors (ICPIs) disrupting PD-1/PD-L1 axis have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Some studies identified the development of endocrine toxicity as predictor of better survival in cancer patients treated with ICPIs. The aim of study was to evaluate survival and new onset of immune-related endocrine adverse events (irAEs) in patients treated with nivolumab for advanced NSCLC. METHODS: In a prospective study, 73 patients with previously treated advanced NSCLC received nivolumab in monotherapy...
April 29, 2024: Journal of Endocrinological Investigation